Apyx Medical Corp
Close on Oct 19, 2026
- Market cap
- $106.12M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $13.90M | $-0.07 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | $12.50M | $-0.05 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $12.90M | $-0.05 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $11.40M | $-0.09 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $9.40M | $-0.10 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | $11.50M | $-0.14 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| operating expenses | year ended December 31, 2026 | $45.00M | Maintained |
| Total revenue | year ending December 31, 2026 | $59.00M to $60.00M | Raised |
| Surgical Aesthetics revenue | year ended December 31, 2026 | $54.00M to $55.00M | Lowered |
| OEM revenue | year ended December 31, 2026 | $5.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Apyx Medical filed with the SEC
Apyx Medical Announces New Clinical Study Demonstrating Renuvion ® ’s Impact on Skin Quality
Other events · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System ™
Other events · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue Results
Results of operations · EX-99.1 to Form 8-K
Medical Corporation Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Apyx Medical Corporation Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System ™
Other events · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED PUBLICATIONS ON THE USE OF RENUVION IN ABDOMINAL BODY CONTOURING PROCEDURES
Other events · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S.
Other events · EX-99.1 to Form 8-K
Medical Corporation Reports Third Quarter 2024 Financial Results;
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Medical Corporation Announces $7,000,000 Million Registered Direct Offering
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Executive or director change · Other events · EX-99.2 to Form 8-K
Apyx Medical Corporation Reports Second Quarter 2024 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports First Quarter 2024 Financial Results;
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication
Other events · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook
Results of operations · EX-99.1 to Form 8-K
Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook
Results of operations · EX-99.1 to Form 8-K